The Effect of Digital Education for Osteoporosis Patients on Fracture Risk and Related Health Outcomes.
NCT ID: NCT06603545
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
2640 participants
INTERVENTIONAL
2024-09-30
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective is to investigate if DEOP compared to standard care (without DEOP), can reduce the incidence of clinical fractures in men and women, over the age of 65 years, without previous osteoporosis medication the last year, who have been recommended osteoporosis treatment after a DXA scan and assessment of clinical risk factors at an osteoporosis clinic.
The secondary objectives are to investigate if DEOP compared to standard care (without DEOP), can reduce the incidence of injurious falls, have positive effects on adherence to osteoporosis medication, positively affect diet (calcium and vitamin D intake), physical activity, and improve quality of life in men and women, over the age of 65 years, without previous osteoporosis medication the last year, who have been recommended osteoporosis treatment after a DXA scan and assessment of clinical risk factors at an osteoporosis clinic.
Study design: randomized multicentre clinical trial. Patients over the age of 65 visiting an osteoporosis unit for a bone density scan (DXA) will be asked to participate in the study. The participants will be randomized to one of two arms where one arm will be invited to DEOP and the other arm will receive standard care, without DEOP.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stop At One Stockholm (SAOS)- Secondary Fracture Prevention Through Active Patient Identification and Staff Education.
NCT04565743
Osteoporosis School
NCT00224991
"Living an Active Life with Osteoporosis" - a Digital Patient Education Program on Osteoporosis. a Feasibility/pilot Study As Part of the PATOS Project (Patient Education in Osteoporosis).
NCT06729424
Osteoporosis Patient Education in Denmark
NCT05401968
Education for Osteoporosis in Persons With Existing Fractures
NCT00575250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The planned study is a multicentre randomized controlled trial, with 9 participating study centers (osteoporosis clinics). Patients who have not previously received osteoporosis medication the last year and are over the age of 65 visiting an osteoporosis clinic for a clinical evaluation, including a bone density scan (DXA) and assessment of clinical risk factors and fracture risk, will be asked to participate in the study. Before the appointment for the DXA measurement, possible study participants will receive written information about the study by mail. At the visit, oral information about the study will be provided by the bone densitometry technologist. Written information will be distributed to possible participants that have not previously received the information. The patients must have the opportunity to ask questions before they make their decision to participate or not. Acceptance to participate must be communicated both verbally and through signing an informed consent form. All patients will undergo a DXA-scan and answer a questionnaire regarding clinical risk factors included in the fracture risk assessment tool FRAX, according to local clinical guidelines.
At a later stage, if the patient, by the doctor at the osteoporosis clinic, is recommended pharmacological treatment for osteoporosis (due to a high fracture risk), the patient becomes eligible for the study. If the patient does not have an indication to receive osteoporosis medication, as judged by the physician at the osteoporosis unit, the patient will be excluded from the study as screening failure and receive a notification of this through e-mail or regular mail.
Patients eligible for the study will be randomized, stratified according to sex and study center, into one of two arms where patients in one arm will be invited to the DEOP and patients in the other arm will receive standard care, without the DEOP. Patients in both groups will be treated and followed according to clinical guidelines for osteoporosis care in their health care region, by either a general practitioner (GP) or a doctor at an osteoporosis clinic. Only osteoporosis clinics without an ongoing DEOP will be eligible as study clinics in these health care regions. After randomization, the local study coordinator will contact all included patients through e-mail or regular mail and ask them to complete self-reported questionnaires regarding physical activity, diet, and quality of life (Physical Activity Scale for the Elderly (PASE), Food Frequency Questionnaire (FFQ), and quality of life (Short Form survey, SF-12), respectively). Data regarding clinical risk factors (and calculated 10-year probability of major osteoporotic fracture and hip fracture) in the fracture risk assessment tool FRAX, height, and weight, and bone mineral density (BMD; of the lumbar spine, total hip, and femoral neck, in grams/cm2 and as T-scores) will be collected from the osteoporosis clinic by the local study coordinator or other study personnel. After years 1 and 3, an e-mail or regular mail (if the study participant does not use e-mail) will be sent to the participants and they will be asked to answer the same questionnaires again. Data regarding clinical fractures will be collected from the Patient Register (Socialstyrelsen, the National Board of Health and Welfare), the Swedish Fracture Register, and from regional X-ray archives after the end of the study (maximum 4 years of follow-up). Data on the incidence of injurious falls (including injuries without fracture) will be collected through the Patient Register at the end of the study. Data on osteoporosis medication use will be collected from the Drug Dispensation Register and regional databases regarding medications provided at health care facilities at the end of the study. Data on deaths will be collected using the National Cause of Death Register. Data on diagnoses and medication will be collected five years back from the inclusion date to determine comorbidity.
The participants in the DEOP group will be given access to the DEOP for four months after randomization. Reminders will be sent out using phone text messages monthly for the first 3 months to participants who have not yet started the DEOP. The control group will be given information regarding fall prevention, physical activity, diet, and osteoporosis medication according to standard care, by their GP or the physician at the osteoporosis clinics, depending on where they are treated for their osteoporosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Digital education for osteoporosis patients (DEOP)
The participants in the DEOP group will be given access to the DEOP for four months after randomization, and can redo the education multiple times within those four months. Reminders will be sent out using phone text messages monthly for the first 3 months to participants who have not yet started the DEOP.
The experimental group will also be given information, according to standard care, regarding fall prevention, physical activity, diet, and osteoporosis medication according to standard care, by their GP or the physician at the osteoporosis clinics, depending on where they are treated for their osteoporosis.
Digital education for osteoporosis patients
DEOP is found on the Swedish health care system's dedicated website or app 1177, it takes approximately 60 minutes to complete and is composed of three modules: 1)Introduction: an animated video that shows the patient flow from having a fracture, being evaluated at the osteoporosis clinic, receiving information about osteoporosis, and being treated for osteoporosis. 2)Osteoporosis: basic information about osteoporosis; why it occurs, risk factors that the patient can affect (such as physical inactivity and smoking), and risk factors that cannot be affected (such as age and heredity). It provides information about typical osteoporotic fractures, and how a patient is evaluated according to clinical guidelines for osteoporosis care. 3)Treatment: information about the different kinds of pharmacological osteoporosis treatment, physical activity, balance control, lifting technique, risk of falling, and dietary advice, especially regarding calcium and vitamin D intake.
No Digital education for osteoporosis patients (DEOP)
The control group will be given information regarding fall prevention, physical activity, diet, and osteoporosis medication according to standard care, by their GP or the physician at the osteoporosis clinics, depending on where they are treated for their osteoporosis.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digital education for osteoporosis patients
DEOP is found on the Swedish health care system's dedicated website or app 1177, it takes approximately 60 minutes to complete and is composed of three modules: 1)Introduction: an animated video that shows the patient flow from having a fracture, being evaluated at the osteoporosis clinic, receiving information about osteoporosis, and being treated for osteoporosis. 2)Osteoporosis: basic information about osteoporosis; why it occurs, risk factors that the patient can affect (such as physical inactivity and smoking), and risk factors that cannot be affected (such as age and heredity). It provides information about typical osteoporotic fractures, and how a patient is evaluated according to clinical guidelines for osteoporosis care. 3)Treatment: information about the different kinds of pharmacological osteoporosis treatment, physical activity, balance control, lifting technique, risk of falling, and dietary advice, especially regarding calcium and vitamin D intake.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to understand and follow study instructions.
* Signed informed consent.
* Have been recommended pharmacological osteoporosis treatment after a clinical evaluation including a DXA-scan and assessment of fracture risk at an osteoporosis clinic.
* Have access to www.1177.se.
Exclusion Criteria
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uppsala University Hospital
OTHER
Region Stockholm
OTHER_GOV
Västernorrland County Council, Sweden
OTHER_GOV
Region Västerbotten
OTHER_GOV
Region Skane
OTHER
Norrbottens Lans Landsting
OTHER
Sahlgrenska University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mattias Lorentzon
Professor, Senior Consultant in Geriatric Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mattias Lorentzon, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Sahlgrenska University Hospital, Västra Götalandsregionen
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DEOP001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.